All lobbying filings

CAPITOL COUNSEL LLC

Lobbying for EMERGENT BIOSOLUTIONS · Bio pharmaceutical company.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 18, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Providing guidance on development, acquisition and stockpiling of medical countermeasures for the US government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA). Funding for medical countermeasure enterprise including, SNS, BARDA and Project BioShield; State Opioid Response (SOR) Grant Funding; Substance Abuse and Mental Health Block Grant (SABG) funding. Naloxone access and awareness and opioid prescribing.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.